Singapore, 9 June 2016 – Homegrown specialty pharmaceutical company iX Biopharma Ltd. (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that it has been granted a patent in South Korea (no. 10-1612073) for its WaferiX™ drug delivery technology. The patent will expire on 26 October 2030.
The grant of the South Korean patent marks another milestone for iX Biopharma, following the success of a recent multi-dose, placebo-controlled clinical study that confirmed the safety and good tolerability of the Group’s lead product, Wafermine™, the first ever oral-sublingual analgesic employing ketamine as an active compound.
WaferiXTM is a fast-dissolving, proprietary wafer formulation that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e., placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream. The WaferiX™ technology offers a non-invasive, pain-free alternative to traditional routes of drug administration such as intravenous drips, injections and oral intake. Key advantages of WaferiX™ include rapid drug absorption and onset of action, better side effect profile, easy administration, improved patient compliance and a better storage profile.
The claims of the patent cover a fast-dissolving oral dosage form for the release of a biologically active material in the oral cavity, and provide strategic coverage for iX Biopharma’s WaferiX™ technology in South Korea. According to the claims of the patent, the particular dosage form may contain and deliver a wide range of biologically active materials and is not limited to a specific biologically active material. Methods for the production of the fast dissolving oral dosage form are also covered.
South Korea is the seventh country to grant iX Biopharma a patent for WaferiX™. The Group was recently granted patents in Japan and Indonesia in September and November 2015 respectively, while counterpart patents have already been granted in Singapore, Australia, New Zealand and Malaysia. Pending applications are currently under examination in the US, Europe, China, India, Canada, South Africa, Hong Kong, Thailand and Vietnam.
About iX Biopharma Ltd
iX Biopharma Ltd is a Singapore public-listed specialty pharmaceutical company, with initial focus on the development and commercialisation of innovative therapies for pain management and men’s health. The Company leverages its patented sublingual drug delivery technology, WaferiX™, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by the United States Food and Drug Administration. It currently has three products under development – Wafermine™ and Wafernyl™ for pain management, and PheoniX™ for erectile dysfunction.
Contact for media:
Ms Alvina Tan
DID: +65 6221 2123 H/P: +65 9787 7267
Email: alvina.tan@arkadvisors.com.sg
Ms Karin Lai
DID: +65 6221 0081 H/P: +65 9837 8136
Email: karin.lai@arkadvisors.com.sg
The grant of the South Korean patent marks another milestone for iX Biopharma, following the success of a recent multi-dose, placebo-controlled clinical study that confirmed the safety and good tolerability of the Group’s lead product, Wafermine™, the first ever oral-sublingual analgesic employing ketamine as an active compound.
WaferiXTM is a fast-dissolving, proprietary wafer formulation that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e., placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream. The WaferiX™ technology offers a non-invasive, pain-free alternative to traditional routes of drug administration such as intravenous drips, injections and oral intake. Key advantages of WaferiX™ include rapid drug absorption and onset of action, better side effect profile, easy administration, improved patient compliance and a better storage profile.
The claims of the patent cover a fast-dissolving oral dosage form for the release of a biologically active material in the oral cavity, and provide strategic coverage for iX Biopharma’s WaferiX™ technology in South Korea. According to the claims of the patent, the particular dosage form may contain and deliver a wide range of biologically active materials and is not limited to a specific biologically active material. Methods for the production of the fast dissolving oral dosage form are also covered.
South Korea is the seventh country to grant iX Biopharma a patent for WaferiX™. The Group was recently granted patents in Japan and Indonesia in September and November 2015 respectively, while counterpart patents have already been granted in Singapore, Australia, New Zealand and Malaysia. Pending applications are currently under examination in the US, Europe, China, India, Canada, South Africa, Hong Kong, Thailand and Vietnam.
About iX Biopharma Ltd
iX Biopharma Ltd is a Singapore public-listed specialty pharmaceutical company, with initial focus on the development and commercialisation of innovative therapies for pain management and men’s health. The Company leverages its patented sublingual drug delivery technology, WaferiX™, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by the United States Food and Drug Administration. It currently has three products under development – Wafermine™ and Wafernyl™ for pain management, and PheoniX™ for erectile dysfunction.
Contact for media:
Ms Alvina Tan
DID: +65 6221 2123 H/P: +65 9787 7267
Email: alvina.tan@arkadvisors.com.sg
Ms Karin Lai
DID: +65 6221 0081 H/P: +65 9837 8136
Email: karin.lai@arkadvisors.com.sg
